Alastair M. Thompson
Surgical Oncology | Oncology | General Surgery
6620 Main St
Suite 1350
Houston, TX 77030
Suite 1350
Houston, TX 77030
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 349 publications
Cellular stemness identifies high-risk ductal carcinoma in situ and offers a therapeutic interception opportunity.
Journal: bioRxiv : the preprint server for biology
Published: May 25, 2026
Erratum: Imaging- and Tumor Biomarker-Based Multivariable Model for Early Prediction of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer.
Journal: JCO precision oncology
Published: May 18, 2026
Mammographic surveillance in breast cancer patients aged 50 years or older: a synopsis of the Mammo-50 RCT.
Journal: Health technology assessment (Winchester, England)
Published: May 12, 2026
Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 25, 2026
Windows of Opportunity in Breast Cancer: Learning More From Fewer Patients in a Shorter Time.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 23, 2026
Elucidating cooperative genetic events in DCIS progression in mutant p53-driven breast cancer.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: January 08, 2026
Imaging- and Tumor Biomarker-Based Multivariable Model for Early Prediction of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer.
Journal: JCO precision oncology
Published: December 18, 2025
Exploration of body mass index and circulating metabolic factors as predictors of metformin benefit in the Canadian Cancer Trials Group MA.32.
Journal: JNCI cancer spectrum
Published: December 17, 2025
Non-BRCA germline pathogenic variants and response to neoadjuvant systemic therapy in triple-negative breast cancer patients enrolled in a prospective clinical trial.
Journal: Breast cancer research and treatment
Published: November 22, 2025
Age-related differences in psychological distress and persistent postsurgical pain after surgery for management of non-invasive breast lesions.
Journal: Breast cancer research and treatment
Published: October 26, 2025
The ARTEMIS trial identifies immune activation as a key predictor of neoadjuvant chemotherapy response in triple-negative breast cancer.
Journal: Breast cancer research : BCR
Published: September 24, 2025
NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors.
Journal: Science translational medicine
Published: August 27, 2025
Last Updated: 09/26/2026